TCS Industries Limited (China-sourced API supplier) supplies Oclacitinib — API CAS 1208319-26-9 for pharmaceutical B2B procurement — COA, MSDS, and technical documentation available on request.
> Overview
| Product Name | Oclacitinib |
|---|---|
| Structural Formula |  |
| CAS Number | 1208319-26-9 |
| Molecular Formula | C₁₅H₂₃N₅O₂S |
| Molecular Weight | 337.4 g/mol |
| InChIKey | HJWLJNBZVZDLAQ-UHFFFAOYSA-N |
| SMILES | Available on request where applicable |
| Appearance | White to off-white powder |
| Purity / Grade | By agreed specification and batch COA |
| Storage | Room temperature |
Oclacitinib Maleate (CAS 1208319-26-9) is a Janus kinase (JAK) inhibitor with the formula C₁₅H₂₃N₅O₂S·C₄H₄O₄ (free base MW 337.46). It preferentially inhibits JAK1 (and to a lesser extent JAK3), blocking cytokine signaling pathways involved in pruritus and inflammation. Oclacitinib is the first JAK inhibitor approved for veterinary use and is used for allergic and atopic dermatitis in dogs.
TCS Industries Limited, a Hong Kong-based trading and sourcing company, supplies Oclacitinib (maleate salt) API for veterinary oral dermatology formulation programs.
> Applications
Canine atopic dermatitis management
Oclacitinib maleate is formulated as film-coated tablets (Apoquel, Zoetis) at 3.6 mg, 5.4 mg and 16 mg strengths. Initial dosing is 0.4–0.6 mg/kg twice daily for 14 days, then once daily for maintenance. Apoquel is indicated for dogs ≥12 months old. Cosgrove et al. (Vet Dermatol, 2013, 24:479–e114) demonstrated rapid onset and sustained efficacy in a 112-day field study of canine atopic dermatitis.
Control of allergic pruritus
Oclacitinib is used for short-term control of pruritus associated with allergic dermatitis in dogs, including flea allergy dermatitis, contact dermatitis and food allergy-related skin signs. The rapid onset (4 hours to itch reduction) provides an advantage over cyclosporine (which takes 4–6 weeks for full effect) and corticosteroids (which carry long-term side effects). Treatment duration and monitoring depend on the underlying cause of allergy.
> Sourcing & Supply
TCS Industries Limited supports development, qualification and commercial purchasing discussions for Oclacitinib with buyers in Australia, New Zealand, Canada and South Korea.
- Development and qualification quantities: 10 g to 1 kg packs for formulation trials, bioequivalence studies, and veterinary drug registration submissions.
- Pallet quantities and production campaigns: repeat supply is coordinated against packaging, lead time, annual demand and destination-market import requirements.
> Quality & Documentation
Key specification parameters include assay (≥98.0%), related substances, loss on drying, residue on ignition, heavy metals, residual solvents, and microbial limits. White to off-white crystalline powder (as maleate salt). Slightly soluble in water. Identity by HPLC, NMR, and MS. Meets in-house veterinary pharmaceutical specifications. COA and MSDS are standard.
> Packaging
Oclacitinib maleate is a white to off-white crystalline powder. Standard packaging includes sealed foil bags under nitrogen in fibre drums (50 g, 100 g, 500 g, or 1 kg). Store at controlled room temperature (15–25 °C). Protect from light and moisture. Shelf life is typically 36 months. Labels and documents are checked before dispatch.
> Pricing & MOQ
Pricing is quoted by specification, packaging and destination. Common commercial discussions use 25 kg bag/drum formats, pallet quantities and production-campaign planning; smaller samples may be reviewed for qualified formulation teams.
> Regulatory & Compounding Context
Oclacitinib maleate is approved for veterinary use only. FDA-CVM approved in 2013 (Apoquel, Zoetis). EMA conditional authorization. Not approved for human use (tofacitinib and baricitinib are human JAK inhibitors). Approved for dogs ≥12 months of age. Under patent in some jurisdictions. Regulatory documentation available.
> Alias Index
- INN: Oclacitinib
- CAS Number: 1208319-26-9 (maleate)
- Formula: C₁₅H₂₃N₅O₂S (free base MW 337.46)
- Brand name: Apoquel (Zoetis)
- ATCvet code: QD11AH90
- Pharmacological class: JAK1 inhibitor
- Related: Tofacitinib (human JAK inhibitor, Xeljanz)
- Commercial request terms: oclacitinib maleate API, Apoquel generic, veterinary JAK inhibitor, canine atopic dermatitis, TCS Industries Limited
> FAQ
How fast does Oclacitinib reduce itch in dogs?
Oclacitinib reduces pruritus within 4 hours of oral administration by blocking JAK1-dependent IL-31 signaling, the primary itch cytokine in canine atopic dermatitis. Clinical signs of inflammation are controlled within 24 hours. This rapid onset distinguishes oclacitinib from cyclosporine, which requires 4–6 weeks for full effect.
What documents are available for Oclacitinib orders?
COA and MSDS are standard for commercial discussions. COO, packing list, invoice and other import-support documents can be arranged according to order scope.
Do you supply Oclacitinib to Australia and Canada?
Yes. We support B2B buyers in Australia, New Zealand, Canada and South Korea, subject to route and document review.
Do you supply New Zealand and South Korea?
Yes. We review Australia, New Zealand, Canada and South Korea for project supply, import documents, packaging and logistics planning before quotation.
Can Oclacitinib be used in dogs under 12 months?
No. Oclacitinib (Apoquel) is not approved for dogs under 12 months of age due to potential immunosuppressive effects during immune system development. It is also not approved for breeding, pregnant or lactating dogs. Buyers should include these contraindications in their product labeling per regulatory requirements.
What is the difference between Oclacitinib and Cyclosporine for canine atopic dermatitis?
Oclacitinib (JAK1 inhibitor) provides rapid itch relief within 4 hours and is dosed orally once daily. Cyclosporine (calcineurin inhibitor, Atopica) takes 4–6 weeks for full effect and is dosed at 5 mg/kg daily. Oclacitinib has faster onset but is restricted to dogs ≥12 months. Both are long-term management options; choice depends on patient age, response and veterinarian preference.
Can you arrange samples before commercial purchasing?
Samples or evaluation quantities may be reviewed for qualified buyers after target specification, application and destination-market requirements are clarified.
How is Oclacitinib packaged for export?
Packaging is confirmed by quantity and material properties. Typical options include foil bags, HDPE containers, fibre drums, 25 kg bags or palletized export packaging.
Can buyer-defined specifications be reviewed?
Yes. Send the specification, methods, impurity limits and required documents. TCS can review feasibility before confirming quotation and lead time.
What payment terms are normally used?
Standard payment is 100% T/T before dispatch unless a different arrangement has been approved for an established commercial account.
What lead time should buyers expect?
Lead time depends on stock, batch size, document scope and destination. Available stock can move faster; made-to-order or pallet programs require longer planning.
Is Oclacitinib related to Tofacitinib?
Both are JAK inhibitors but with different selectivity profiles. Oclacitinib (CAS 1208319-26-9, Apoquel) preferentially inhibits JAK1 and is approved for veterinary use in dogs. Tofacitinib (CAS 540737-29-9, Xeljanz) inhibits JAK1/JAK3 and is approved for human rheumatoid arthritis. They are structurally different compounds with different CAS numbers and regulatory pathways.
Last reviewed: June 2026
Evaluation and research orders (≤10 kg) are shipped with COA, MSDS, and certificate of origin. Bulk commercial orders (>10 kg) qualify for volume pricing with a full technical documentation package available on request.
> Request a Quote
If your team already has a target application, estimated quantity, destination market, or documentation requirements, send those details so the commercial response can be prepared more efficiently.